Radhakrishnan Ramchandren

Author PubWeight™ 19.00^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.	J Clin Oncol	2012	6.78
2	Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.	J Clin Oncol	2012	4.41
3	Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.	J Clin Oncol	2013	2.07
4	Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.	Blood	2012	1.67
5	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.	J Hematol Oncol	2014	1.18
6	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.	Leuk Lymphoma	2015	0.95
7	Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.	Invest New Drugs	2014	0.90
8	CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.	J Clin Pharmacol	2013	0.86
9	Cryptococcus albidus infection in a patient undergoing autologous progenitor cell transplant.	Transplantation	2004	0.82
10	Transformed aggressive γδ-variant T-cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11.2q25.3 and additional aberrations.	Eur J Haematol	2014	0.75